Mind Medicine Sees CEO Sell $24.7 Million In Company Stock

It appears that uplisting to the Nasdaq is good for business. Or, at least for liquidity, as per insider action that was reported on Mind Medicine (NEO: MMED) (NASDAQ: MNMD) last night. The company has seen its CEO, JR Rahn, sell off a significant portion of his holdings in the company.

As per filings made last night, the firms chief executive has sold off approximately $24.7 million in company stock over the course of approximately one week. Sales consisted of subordinate voting shares of the issuer, as well as the exercise of options and restricted share units.

In total, Rahn sold 6.45 million subordinate voting shares of the issuer, after having exercised a total of 1.9 million options and 727,187 restricted share units. Following the transaction, Rahn now holds 5.3 million options, 2.0 million RSU’s, and just 1.7 million subordinate voting shares.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

It’s believed that on a cumulative basis, the sale represented approximately 38% of Rahn’s total position in the company once factoring in subordinates shares, options, and RSU’s.

—–
Correction: As a result of multiple voting shares, it appears that only 38% of Rahn’s position was sold, rather than the originally stated 44%.
—-

Mind Medicine last traded at $3.79 on the NEO.


Information for this briefing was found via Sedar, Sedi and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Is Agnico Eagle Seabridge Gold’s Mystery Lender?

This Gold Giant Is Building 1.5 Million More Ounces a Year | Agnico Eagle Q3 Earnings

This Gold Giant Was a Mess. Now It’s Back! | Barrick Mining Q3 2026 Earnings

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

MindMed Acquires HealthMode For $41.6 Million

MindMed (NEO: MMED) this morning announced that it will be acquiring that of HealthMode in...

Thursday, February 18, 2021, 08:21:32 AM

Mindmed Completes 15-To-1 Reverse Split To Maintain Nasdaq Compliance

Mind Medicine (NEO: MMED) might be slightly more volatile over the next few sessions. The...

Monday, August 29, 2022, 08:21:39 AM

Mindmed To Conduct 15-To-1 Reverse Split To Meet Nasdaq Listing Requirements

In a classic Canadian small cap move, Mind Medicine (NEO: MMED) last night announced that...

Friday, August 5, 2022, 08:42:02 AM

Mind Medicine Announces $50 Million Bought Deal Financing Days After Raising $34.5 Million

Mind Medicine (NEO: MMED) is raising even more cash. The company this evening announced that...

Monday, December 14, 2020, 08:43:58 PM

MindMed’s Mescaline Study Approved For Clinical Trial

MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects...

Thursday, May 20, 2021, 08:38:23 AM